Gilead Sciences Files 8-K Report

TL;DR

Gilead filed an 8-K on 10/6/25. Standard disclosure, no major news yet.

AI Summary

On October 6, 2025, Gilead Sciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Gilead Sciences is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate adverse events.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• October 6, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 333 Lakeside Drive, Foster City, California 94404 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select

Filing Documents

• gild-20251006.htm (8-K) — 26KB
• 0000882095-25-000041.txt ( ) — 139KB
• gild-20251006.xsd (EX-101.SCH) — 2KB
• gild-20251006_lab.xml (EX-101.LAB) — 21KB
• gild-20251006_pre.xml (EX-101.PRE) — 12KB
• gild-20251006_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 6, 2025, Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced that it has entered into settlement agreements ("Agreements") to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy . Under the Agreements, which are subject to standard acceleration provisions, no generic entry is expected prior to April 1, 2036 in the United States for Biktarvy tablets containing bictegravir (50 mg), emtricitabine (200 mg) and tenofovir alafenamide (25 mg). This filing includes forward-looking statements that are subject to the safe harbors provided under the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any statement other than statements of historical fact are forward-looking statements, including statements regarding patent protection and estimated loss of exclusivity for our products, and involve risks and uncertainties that may cause actual results or outcomes to differ materially. These risks and uncertainties include challenges to intellectual property, adverse litigation or government action, changes to laws and regulations applicable to our industry, as well as other risks and uncertainties described in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as filed with the U.S. Securities and Exchange Commission (the "SEC"). The forward-looking statements included in this filing are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of the SEC, Gilead does not undertake, and specifically declines, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after this fil

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ DEBORAH H. TELMAN Deborah H. Telman EVP, Corporate Affairs, General Counsel and Corporate Secretary Date: October 6, 2025

View Full Filing

View this 8-K filing on SEC EDGAR